Pharmally International Holding Company Limited (hereinafter ‘Pharmally’) was established in 2013 with the registered capital of TWD1 billion. The current share capital of Pharmally is TWD0.68 billion and the number of employees is about 1,200. Luan Worldbest Pharmaceutical Company Limited (hereinafter ‘Luan Worldbest’), the wholly-own subsidiary of Pharmally, is the production base of Pharmally, with an area of 300 acres. Luan Worldbest focuses on the production and development of Large Volume Parental (LVP) and Active Pharmaceutical Ingredient (API), and currently owns 10 production lines of LVP, 2 production workshops for API, product approval for 9 kinds of APIs and 55 kinds of LVPs. The annual production capacity of Luan Worldbest: bottle LVP of 250 million bottles/year, polypropylene LVP of 195 million bottles/year, soft bag LVP(Non-PVC co-extruded film bags) of 185 million bags/year, Nikethamide of 300 tons/year, and Levofloxacin Lactate of 160 tons/year.
At present, the company is actively involved in the production of animal vaccines, cooperating with Harbin Weike Biotechnology Development Company, which owns the most advanced bird flu vaccine technology in the world, to set up a poultry vaccine manufacturing enterprise in Indonesia, so as to expand its growth. By expanding overseas, the company will diversify its pharmaceutical products, from the production of human pharmaceuticals to the production of animal vaccines. It will also speed up the internationalization strategy of Pharmally, extending the market from China to Indonesia and even Asean.
Regarding the quality as lifeline, Pharmally followed the most stringent standards of operation from the construction of the plant to the production process control. We strictly monitor air, water and power to create a zero-pollution production environment. Through the first-class production equipment, the Company improved efficiency significantly, realized clean production, reduced environmental protection costs, and implemented safety responsibility system and standardized on-site management, to effectively control operation quality.
With the promotion of the new rural cooperative medical policy, the demand for LVPs and APIs will continue to grow. Meanwhile, Pharmally, which is located in the three major agricultural provinces in the Mainland China, will continue to strengthen its production technology, introduce more advanced production equipment, and expand its production capacity and scale. It is hoped that through our efforts, we will guard people's health and create a better future.